In addition, in the subgroup analysis, QTc of the two groups also showed significant changes earlier than LVEF in the case of coronary heart disease and sequential treatment of anthracene, suggesting that the change of QTc may be earlier than LVEF in some cases during anti-HER2-targeted therapy. This evidence concerns the gene ERBB2 and coronary artery disorder.